Current status of novel antifibrotic therapies in patients with chronic liver disease - Wikidata - awgldk - TriplyDB

Current status of novel antifibrotic therapies in patients with chronic liver disease

Current status of novel antifibrotic therapies in patients with chronic liver disease

http://www.wikidata.org/entity/Q30473375

about

Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update Protection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stress Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B.Comparing hepatic 2D and 3D magnetic resonance elastography methods in a clinical setting - Initial experiences.Soluble biglycan as a biomarker of inflammatory renal diseases.Mutant MMP-9 and HGF gene transfer enhance resolution of CCl4-induced liver fibrosis in rats: role of ASH1 and EZH2 methyltransferases repression Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.Supplementation of fresh ucche (Momordica charantia L. var. muricata Willd) prevented oxidative stress, fibrosis and hepatic damage in CCl4 treated rats.Discovery of Peptide ligands for hepatic stellate cells using phage display Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.A Human Anti-Toll Like Receptor 4 Fab Fragment Inhibits Lipopolysaccharide-Induced Pro-Inflammatory Cytokines Production in Macrophages.A bioinformatic and mechanistic study elicits the antifibrotic effect of ursolic acid through the attenuation of oxidative stress with the involvement of ERK, PI3K/Akt, and p38 MAPK signaling pathways in human hepatic stellate cells and rat liver.Characterization of the MMP/TIMP Imbalance and Collagen Production Induced by IL-1β or TNF-α Release from Human Hepatic Stellate Cells.Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer Downregulation of UBC9 promotes apoptosis of activated human LX-2 hepatic stellate cells by suppressing the canonical NF-κB signaling pathway Preventive effects of phenylethanol glycosides from Cistanche tubulosa on bovine serum albumin-induced hepatic fibrosis in rats.Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.Natural killer and natural killer T cells in liver fibrosis Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts.A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response.Macrophage Migration Inhibitor Factor Upregulates MCP-1 Expression in an Autocrine Manner in Hepatocytes during Acute Mouse Liver Injury.Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways.Modulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells.Hepatitis C Virus Infection of Cultured Human Hepatoma Cells Causes Apoptosis and Pyroptosis in Both Infected and Bystander Cells.The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease.Fatty acid-regulated transcription factors in the liver.Hepatic inflammation and progressive liver fibrosis in chronic liver disease.A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats.Review article: the reversibility of cirrhosis.Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever.Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar.

P2860

Q26752622-D04A58A6-D801-4F97-9D84-BE6AAC2CDA3B Q26771779-863B2C5A-BA51-444D-889C-B76DBC7194B9 Q26773384-E7097162-2628-4CC9-96F2-0B430A103FE6 Q26775036-D4A25B49-98DD-43A6-B57B-E3D3BAF3F270 Q27027703-813E45BC-54D5-4305-869A-638C580BF8CA Q28539856-315AE1A9-AA31-4B86-8CD3-6F1B9F4395D9 Q30383907-06D566D7-6811-4D72-929B-4DEC5067CC17 Q30389303-766F758B-EFC8-43A8-B778-0A0257106688 Q34160971-AD8FE157-1E2C-4266-8445-CE11932D99F8 Q34473076-B41D13F0-103C-4135-8105-345FE08435AA Q34985947-E2C2FFD9-387C-4282-8D71-2D5F15E1AE7F Q35196346-E974459C-1CEA-445C-BD3A-78094AE209BD Q35580197-6B788F0E-1521-4C95-A819-D975AC0DC35B Q35625290-AA7E5F54-1D78-4F78-A5A2-027E6D212961 Q35651447-82A9E008-3F7A-4F7B-A47D-E0E007693899 Q35898018-90D75736-085F-4AB4-8B11-1CC8D2CE17FC Q35928666-5C162D59-5529-4573-95EC-C8E265677E21 Q35980026-5B3871D6-4FCC-4F6B-8FE6-B8C25E61AE8C Q36003201-B4C043C6-1533-4045-B1D1-57E7944DC3C9 Q36083434-BA14E32D-F32C-433E-B10E-C1EEA7A92209 Q36273224-2E28F03C-AB67-44AA-B7B9-0BD5D73B7EF6 Q36328115-F8B2F139-C697-45D4-8283-496389A801D7 Q36357775-D26C42DD-4B0D-446D-BA45-600BD01AE4D7 Q36483906-7D6A2CB9-8D51-445B-B8C4-400103F1F3BE Q36553227-B506A142-8E25-4394-B818-77B1E45BF3B4 Q36698872-7AC20395-5C7A-450F-9C0F-29E141470117 Q36826814-D6E2A1FD-0560-4BF3-86DF-1B190F116D9C Q36905046-4C40326D-1EBE-4F4D-8C01-EE7FDDFC673B Q36980410-6BAAE90A-EEF1-4489-A799-A6D96DDB311C Q37112309-3E7510B0-3ED0-4BFC-90A8-E15B627B48FB Q37192466-F3CF3320-5700-44F7-9C1A-F6B853CE2AA1 Q37504457-48B051EA-2F8E-4E33-AFC9-9C00311DB6F4 Q37552230-47202BD5-02C5-4790-B415-028937AFF9FD Q37613511-06658F37-CA84-4267-BD33-FB79FE0FCE3B Q37629675-69F9DC70-EF57-4876-B829-66C9D7D7629C Q37729132-B1A5A3C7-4450-48C4-8F28-B66B313AFE50 Q38042443-BA645D10-AD15-46B9-967A-92575B52B9E5 Q38175465-CABDD9E8-90B0-47BA-97D1-35084864266C Q38176402-2CD875E6-A00D-43E3-89AA-635F1B64C775 Q38218544-991EABDD-916F-434D-B28D-BED632E56121

P2860

Current status of novel antifibrotic therapies in patients with chronic liver disease

http://www.wikidata.org/entity/Q30473375

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Current status of novel antifibrotic therapies in patients with chronic liver disease

@ast

Current status of novel antifibrotic therapies in patients with chronic liver disease

@en

type

label

Current status of novel antifibrotic therapies in patients with chronic liver disease

@ast

Current status of novel antifibrotic therapies in patients with chronic liver disease

@en

prefLabel

Current status of novel antifibrotic therapies in patients with chronic liver disease

@ast

Current status of novel antifibrotic therapies in patients with chronic liver disease

@en

P1433

Q30473375-5E2A3143-A8F0-465C-8EE7-E62C5189CF30

P1476

Q30473375-BDD9D4EA-56BC-4D19-8895-3E162E563F8B

P2093

Q30473375-5AF71D75-156C-418D-B349-069A780D647C

Q30473375-A7C0556A-3BCD-44F2-B3F4-D48A3056929B

P2860

Q30473375-0086A6D5-8BFA-4F8F-BC3A-476EC499471D

Q30473375-013B93E6-8C39-4ACB-B382-D900E9D0190E

Q30473375-03D63FDE-6BE7-4A8B-86FD-A3FB39FE5F06

Q30473375-06F04F75-A054-400D-8248-6222B3E696C0

Q30473375-08088CFE-5937-4214-841E-BF1325022EF1

Q30473375-0920E273-731A-49E7-BF6E-EBD7792BC04F

Q30473375-0BD16564-0270-4CE4-AB98-802A9481C8C1

Q30473375-0D3BC552-88E1-44F5-BE25-6F33A45C379A

Q30473375-0D9BD05C-7DB1-42DD-ABEC-A39091609552

Q30473375-0ECDE9FD-E7C8-4829-8753-979C52843782

P304

Q30473375-679A81BB-7EC2-4971-A768-41825076786E

P31

Q30473375-2E1F864F-79A9-4CAF-A61B-5528736C11DF

P356

Q30473375-EEB2E679-7D7D-4223-99C1-D3AC08C29DDF

P433

Q30473375-CF7A90F5-B908-4482-AEC6-7533B871C8F1

P478

Q30473375-07DEDD0B-E9F9-498A-B5A5-0BDA453F2FCE

P577

Q30473375-2F0D254D-1B32-4D3C-A8E9-00E701562AAE

P5875

Q30473375-D28F1349-66A6-4F35-A21F-3A0A4A25C219

P698

Q30473375-BF2AA692-1362-4E44-BA39-819F216F7559

P932

Q30473375-61BC11B0-E5BF-4BCF-85D7-7C19A3ABBDE9

P356

1756283X11413002

P1433

Therapeutic Advances in Gastroenterology

P1476

Current status of novel antifibrotic therapies in patients with chronic liver disease

@en

P2093

Michal Cohen-Naftaly

http://www.w3.org/2001/XMLSchema#string

Scott L Friedman

http://www.w3.org/2001/XMLSchema#string

P2860

Role of LXRs in control of lipogenesis

Senescence of activated stellate cells limits liver fibrosis

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial

Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon

Coffee, cirrhosis, and transaminase enzymes

Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy

Ito cells are liver-resident antigen-presenting cells for activating T cell responses

A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis

P304

391-417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X11413002

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51760535

http://www.w3.org/2001/XMLSchema#string

P698

22043231

http://www.w3.org/2001/XMLSchema#string

P932

3187682

http://www.w3.org/2001/XMLSchema#string